Practice Trends in the Diagnosis and Management of Prostate Cancer in the United States

The Journal of Urology

Volumn 154, Issue 1, 1995, Pages 207-208

  Gee, William F ^a   Holtgrewe, H Logan ^a   Albertsen, Peter C ^a   Litwin, Mark S ^a   Manyak, Michael J ^a   O'Leary, Michael P ^a   Painter, M Ray ^a  

^a American Urological Association   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ARTICLE; CANCER DIAGNOSIS; CANCER HORMONE THERAPY; HUMAN; MAJOR CLINICAL STUDY; MEDICAL PRACTICE; ORCHIECTOMY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; UNITED STATES;

ADULT; AGED; CYSTOSCOPY; FLUTAMIDE; GONADORELIN; HUMAN; MALE; NEOPLASM STAGING; ORCHIECTOMY; PHYSICIAN'S PRACTICE PATTERNS; PROFESSIONAL PRACTICE; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; SOCIETIES, MEDICAL; UNITED STATES; UROGRAPHY; UROLOGY;

EID: 0029002134     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(01)67270-7     Document Type: Article

References (6)

1. Practice trends in diagnosis and management of benign prostatic hyperplasia in the United States
2. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters
3. The use of prostate-specific antigen in staging patients with newly diagnosed prostate cancer
4. Using PSA to eliminate the staging radionuclide bone scan. Significant economic implications